Figure 1 (Dalfampridine Figure1)
This is not a clear description.*
Dalfampridine Tablet, Extended Release
Product Images NDC 72162-2459
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Dalfampridine (NDC 72162-2459). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 (Dalfampridine Figure2)
Average Percent Increase in Walking Speed from Baseline is being evaluated based on the percentage of patients who received different treatments. The data shows the percentage of patients in each group - Placebo, Dllamride Extended Release Tablet 10mg bid, with statistical values provided. The average percent increase in walking speed from baseline is also presented.*
Structure (Dalfampridine Structure)
Label (Lbl721622459)
This is a product label for tablets containing 10 mg of Dalfampridine and it includes dosage information, storage instructions, and manufacturer details. The tablets are extended-release and should be taken whole without dividing, crushing, chewing, or dissolving. The label also mentions the National Drug Code (NDC) and advises keeping the medication out of reach of children. Additionally, the package should be dispensed with a pharmaceutical guide for each patient and in containers with child-resistant closures. The tablets should be stored at 15° to 30°C (59° to 86°F).*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
